SUMMARY: Breast cancer is the most common cancer among women in the US and about 1 in 8 women (12%) will develop invasive breast cancer during their lifetime. It is estimated that in the US, approximately 321,910 new cases of female breast cancer will be diagnosed in 2026, and about 42,140 women will die of the disease, largely due to metastatic recurrence.
The Evolving Role of Breast MRI in Clinical Practice
Breast Magnetic Resonance Imaging (MRI) has become an important adjunct to mammography and ultrasound across a range of clinical scenarios. Its high sensitivity makes it particularly valuable in complex cases where conventional imaging may be limited, such as dense breast tissue or multifocal disease. As utilization has expanded, a critical question has emerged: does the additional disease detected by breast MRI translate into improved oncologic outcomes?
Established Clinical Indications for Breast MRI
Breast MRI is most clearly supported in selected high-risk and diagnostic settings, where its superior sensitivity can meaningfully inform care.
High-Risk Screening
MRI is recommended for patients with a substantially elevated lifetime risk of breast cancer, including those with:
- Pathogenic BRCA1/2 variants or first-degree relatives of known carriers
- Hereditary cancer syndromes such as Li-Fraumeni or Cowden syndrome
- Prior therapeutic chest irradiation between ages 10 and 30
- A calculated lifetime breast cancer risk of ≥20–25% using validated risk models
Evaluation of Known Breast Cancer (Staging and Extent)
In patients with newly diagnosed breast cancer, MRI may help define disease burden when conventional imaging is insufficient:
- Detection of multifocal or multicentric disease, including contralateral breast involvement
- Improved visualization in dense breast tissue
- Enhanced detection of invasive lobular carcinoma, which can be underestimated on mammography
- Identification of occult primary tumors in patients presenting with axillary adenopathy
- Assessment of posterior lesions and potential chest wall involvement
Diagnostic Evaluation of Symptoms or Indeterminate Findings
MRI is also used selectively to clarify challenging diagnostic scenarios, including:
- Pathologic nipple discharge or suspected Paget disease
- Indeterminate mammographic or ultrasound findings that cannot be confidently biopsied
- Evaluation of breast implant integrity
- Unexplained new nipple inversion
Treatment Monitoring and Post-Treatment Assessment
In the therapeutic setting, breast MRI may assist with:
- Monitoring response to neoadjuvant chemotherapy
- Evaluating residual disease after breast-conserving surgery
- Distinguishing post-treatment changes from locoregional recurrence
While these indications are well accepted, the impact of breast MRI on long-term outcomes in newly diagnosed breast cancer has remained uncertain.
Does Preoperative Breast MRI Improve Outcomes? Insights from Alliance A011104
Trial Rationale and Design
Despite widespread adoption of preoperative breast MRI for local staging and surgical planning, robust evidence demonstrating improved oncologic outcomes has been limited. The Alliance A011104 phase III trial was designed to directly address whether identifying mammographically occult disease with MRI, and modifying surgery accordingly, reduces local-regional recurrence.
This randomized study enrolled 319 patients with newly diagnosed clinical Stage I–II breast cancer who were eligible for breast-conserving surgery and had biologically aggressive disease, including Triple-Negative breast cancer or Hormone Receptor-negative/HER2-positive tumors. Patients with germline BRCA mutations, bilateral disease, or prior breast cancer were excluded. Participants were randomly assigned to undergo preoperative breast MRI within 30 days of diagnostic mammography or to proceed without MRI.
Patient Characteristics and Treatment
The median age at enrollment was approximately 59 years, with most patients presenting with small, node-negative tumors. Systemic therapy was commonly employed, with 85% of patients receiving chemotherapy and a subset treated in the neoadjuvant setting. Importantly, presurgical ultrasound, while not mandated, was widely utilized across institutions, reflecting contemporary practice.
Key Findings: No Improvement in Local-Regional Control
With a median follow-up exceeding five years, the trial demonstrated no significant difference in local-regional outcomes between the MRI and no-MRI arms.
- Rates of breast-conserving surgery were high and comparable between groups
- The majority of patients underwent sentinel lymph node biopsy alone
- Pathologic Complete Response rates among patients receiving neoadjuvant chemotherapy did not differ significantly between arms
- Adjuvant radiation use was similar in both groups
Among patients evaluable for the Primary endpoint, 5-year local-regional control exceeded 90% in both arms, with no statistically meaningful difference observed. Distant Recurrence-Free Survival and Overall Survival were also excellent and equivalent regardless of MRI use.
Exploratory subgroup analyses failed to identify any patient population that derived a local control benefit from preoperative MRI.
Interpreting the Results: Why Was No Benefit Observed?
Several explanations may account for the lack of observed advantage with preoperative breast MRI. First, contemporary multimodality therapy, including effective systemic treatment and radiation, may adequately control small foci of disease detected only by MRI, reducing the necessity for surgical excision. Second, advances in mammographic technology and the routine incorporation of ultrasound may have narrowed the incremental value of MRI for local staging compared with earlier eras.
Ongoing analyses from the trial are exploring whether MRI influences other surgical outcomes, such as margin status and reoperation rates.
Clinical Implications and Take-Home Message
In patients with early-stage Triple-Negative or HER2-positive breast cancer treated with modern multimodality therapy, local-regional recurrence rates are low. Results from Alliance A011104 indicate that routine use of preoperative breast MRI for local staging and surgical planning does not improve local-regional control in this setting.
These findings support a more selective, indication-driven approach to breast MRI, reserving its use for high-risk screening, specific diagnostic dilemmas, and carefully chosen staging scenarios, rather than routine deployment in all newly diagnosed patients.
As imaging technologies and systemic therapies continue to evolve, ongoing evaluation of how best to integrate advanced imaging into patient-centered, value-based care remains essential.
Effect of Preoperative Breast MRI Staging on Local Regional Recurrence (LRR) in Early Stage Breast cancer: Alliance A011104/ACRIN 6694. Bedrosian I, Ballman K, McCall LM, et al. Presented at the 2025 San Antonio Breast Cancer Symposium; December 9-12, 2025; San Antonio, TX. Abstract GS2-07.
